Neuroimaging in Pediatric Patients with Juvenile Xanthogranuloma of the CNS

References

1. 1.↵
   1. Deisch JK,
   2. Patel R,
   3. Koral K, et al

   . Juvenile xanthogranulomas of the nervous system: a report of two cases and review of the literature. Neuropathology 2013;33:39–46 doi:10.1111/j.1440-1789.2012.01323.x pmid:22640164

   CrossRefPubMed
2. 2.↵
   1. Wang B,
   2. Jin H,
   3. Zhao Y, et al

   . The clinical diagnosis and management options for intracranial juvenile xanthogranuloma in children: based on four cases and another 39 patients in the literature. Acta Neurochir (Wien) 2016;158:1289–97 doi:10.1007/s00701-016-2811-7 pmid:27173098

   CrossRefPubMed
3. 3.↵
   1. Hock M,
   2. Zelger B,
   3. Schweigmann G, et al

   . The various clinical spectra of juvenile xanthogranuloma: imaging for two case reports and review of the literature. BMC Pediatr 2019;19:128 doi:10.1186/s12887-019-1490-y pmid:31018833

   CrossRefPubMed
4. 4.↵
   1. Szczerkowska-Dobosz A,
   2. Kozicka D,
   3. Purzycka-Bohdan D, et al

   . Juvenile xanthogranuloma: a rare benign histiocytic disorder. Postepy Dermatol Alergol 2014;31:197–200 doi:10.5114/pdia.2014.40918 pmid:25097495

   CrossRefPubMed
5. 5.↵
   1. McClain KL,
   2. Bigenwald C,
   3. Collin M, et al

   . Histiocytic disorders. Nat Rev Dis Primers 2021;7:73 doi:10.1038/s41572-021-00307-9 pmid:34620874

   CrossRefPubMed
6. 6.↵
   1. Meshkini A,
   2. Shahzadi S,
   3. Zali A, et al

   . Systemic juvenile xanthogranuloma with multiple central nervous system lesions. J Cancer Res Ther 2012;8:311–13 doi:10.4103/0973-1482.99001 pmid:22842385

   CrossRefPubMed
7. 7.↵
   1. Rajendra B,
   2. Duncan A,
   3. Parslew R, et al

   . Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. Pediatr Blood Cancer 2009;52:413–45 doi:10.1002/pbc.21830 pmid:18989881

   CrossRefPubMed
8. 8.↵
   1. Emile JF,
   2. Abla O,
   3. Fraitag S

   , et al; Histiocyte Society. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016;127:2672–81 doi:10.1182/blood-2016-01-690636 pmid:26966089

   Abstract/FREE Full Text
9. 9.↵
   1. Janssen D,
   2. Harms D

   . Juvenile xanthogranuloma in childhood and adolescence: a clinicopathologic study of 129 patients from the Kiel Pediatric Tumor Registry. Am J Surg Pathol 2005;29:21–28 doi:10.1097/01.pas.0000147395.01229.06 pmid:15613853

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Freyer DR,
    2. Kennedy R,
    3. Bostrom BC, et al

    . Juvenile xanthogranuloma: forms of systemic disease and their clinical implications. J Pediatr 1996;129:227–37 doi:10.1016/s0022-3476(96)70247-0 pmid:8765620

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Diamond EL,
    2. Durham BH,
    3. Ulaner GA, et al

    . Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 2019;567:521–24 doi:10.1038/s41586-019-1012-y pmid:30867592

    CrossRefPubMed
12. 12.↵
    1. Kemps PG,
    2. Picarsic J,
    3. Durham BH, et al

    . ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood 2022;139:256–80 doi:10.1182/blood.2021013338 pmid:34727172

    CrossRefPubMed
13. 13.↵
    1. Ernemann U,
    2. Skalej M,
    3. Hermisson M, et al

    . Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis. Neuroradiology 2002;44:759–63 doi:10.1007/s00234-002-0819-6 pmid:12221448

    CrossRefPubMed
14. 14.↵
    1. Gressot LV,
    2. Patel AJ,
    3. Bollo RJ, et al

    . Disseminated intracranial juvenile xanthogranulomatosis in a neonate without cutaneous lesions. J Neurosurg Pediatr 2013;12:187–91 doi:10.3171/2013.5.PEDS1332 pmid:23790105

    CrossRefPubMed
15. 15.↵
    1. Orsey A,
    2. Paessler M,
    3. Lange BJ, et al

    . Central nervous system juvenile xanthogranuloma with malignant transformation. Pediatr Blood Cancer 2008;50:927–30 doi:10.1002/pbc.21252 pmid:17520744

    CrossRefPubMed
16. 16.↵
    1. Field AP

    . Discovering Statistics Using SPSS (Introducing Statistical Methods). 3rd ed. SAGE Edge; 2009
17. 17.↵
    1. Writing Group of the Histiocyte Society

    . Histiocytosis syndromes in children. Lancet 1987;1:208–09 pmid:2880029

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Favara BE,
    2. Feller AC,
    3. Pauli M, et al

    . Contemporary classification of histiocytic disorders: the WHO Committee on Histiocytic/Reticulum Cell Proliferations—Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997;29:157–66 doi:10.1002/(SICI)1096-911X(199709)29:3<157::AID-MPO1>3.0.CO;2-c pmid:9212839

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Isaacs H Jr.

    Fetal and neonatal histiocytoses. Pediatr Blood Cancer 2006;47:123–29 doi:10.1002/pbc.20725 pmid:16416419

    CrossRefPubMed
20. 20.↵
    1. Lalitha P,
    2. Reddy M,
    3. Reddy KJ

    . Extensive intracranial juvenile xanthogranulomas. AJNR Am J Neuroradiol 2011;32:E132–33 doi:10.3174/ajnr.A2209 pmid:20671061

    Abstract/FREE Full Text
21. 21.↵
    1. Patrizi A,
    2. Neri I,
    3. Bianchi F, et al

    . Langerhans cell histiocytosis and juvenile xanthogranuloma: two case reports. Dermatology 2004;209:57–61 doi:10.1159/000078589 pmid:15237270

    CrossRefPubMed
22. 22.↵
    1. Picarsic J,
    2. Pysher T,
    3. Zhou H, et al

    . BRAF V600E mutation in juvenile xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Acta Neuropathol Commun 2019;7:168 doi:10.1186/s40478-019-0811-6 pmid:31685033

    CrossRefPubMed
23. 23.↵
    1. Ali MM,
    2. Gilliam AE,
    3. Ruben BS, et al

    . Juvenile xanthogranuloma in Noonan syndrome. Am J Med Genet A 2021;185:3048–52 doi:10.1002/ajmg.a.62353 pmid:34032360

    CrossRefPubMed
24. 24.↵
    1. Liy-Wong C,
    2. Mohammed J,
    3. Carleton A, et al

    . The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: a retrospective case-control study. J Am Acad Dermatol 2017;76:1084–87 doi:10.1016/j.jaad.2016.12.012 pmid:28189268

    CrossRefPubMed
25. 25.↵
    1. Cambiaghi S,
    2. Restano L,
    3. Caputo R

    . Juvenile xanthogranuloma associated with neurofibromatosis 1: 14 patients without evidence of hematologic malignancies. Pediatr Dermatol 2004;21:97–101 doi:10.1111/j.0736-8046.2004.21201.x pmid:15078345

    CrossRefPubMed
26. 26.↵
    1. Zvulunov A,
    2. Barak Y,
    3. Metzker A

    . Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia; world statistical analysis. Arch Dermatol 1995;131:904–08 doi:10.1001/archderm.1995.01690200040007 pmid:7632061

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Durham BH,
    2. Lopez Rodrigo E,
    3. Picarsic J, et al

    . Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nat Med 2019;25:1839–42 doi:10.1038/s41591-019-0653-6 pmid:31768065

    CrossRefPubMed
28. 28.↵
    1. Ginat DT,
    2. Vargas SO,
    3. Silvera VM, et al

    . Imaging features of juvenile xanthogranuloma of the pediatric head and neck. AJNR Am J Neuroradiol 2016;37:910–16 doi:10.3174/ajnr.A4644 pmid:26744443

    Abstract/FREE Full Text
29. 29.↵
    1. Dehner LP

    . Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol 2003;27:579–93 doi:10.1097/00000478-200305000-00003 pmid:12717244

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Prosch H,
    2. Grois N,
    3. Wnorowski M, et al

    . Long-term MR imaging course of neurodegenerative Langerhans cell histiocytosis. AJNR Am J Neuroradiol 2007;28:1022–28 doi:10.3174/ajnr.A0509 pmid:17569949

    CrossRefPubMed
31. 31.↵
    1. Prayer D,
    2. Grois N,
    3. Prosch H, et al

    . MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis. AJNR Am J Neuroradiol 2004;25:880–91 pmid:15140741

    PubMedWeb of Science
32. 32.↵
    1. Yeh EA,
    2. Greenberg J,
    3. Abla O, et al

    ; North American Consortium for Histiocytosis. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: current views and new vistas. Pediatr Blood Cancer 2018;65:e26784 doi:10.1002/pbc.26784 pmid:28944988

    CrossRefPubMed
33. 33.↵
    1. Boyd LC,
    2. O'Brien KJ,
    3. Ozkaya N, et al

    . Neurological manifestations of Erdheim-Chester Disease. Ann Clin Transl Neurol 2020;7:497–506 doi:10.1002/acn3.51014 pmid:32227455

    CrossRefPubMed